Molecular target class is predictive of in vitro response profile
- PMID: 20406975
- DOI: 10.1158/0008-5472.CAN-09-3788
Molecular target class is predictive of in vitro response profile
Abstract
Preclinical cellular response profiling of tumor models has become a cornerstone in the development of novel cancer therapeutics. As efforts to predict clinical efficacy using cohorts of in vitro tumor models have been successful, expansive panels of tumor-derived cell lines can recapitulate an "all comers" efficacy trial, thereby identifying which tumors are most likely to benefit from treatment. The response profile of a therapy is most often studied in isolation; however, drug treatment effect patterns in tumor models across a diverse panel of compounds can help determine the value of unique molecular target classes in specific tumor cohorts. To this end, a panel of 19 compounds was evaluated against a diverse group of cancer cell lines (n = 311). The primary oncogenic targets were a key determinant of concentration-dependent proliferation response, as a total of five of six, four of four, and five of five phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, insulin-like growth factor-I receptor (IGF-IR), and mitotic inhibitors, respectively, clustered with others of that common target class. In addition, molecular target class was correlated with increased responsiveness in certain histologies. A cohort of PI3K/AKT/mTOR inhibitors was more efficacious in breast cancers compared with other tumor types, whereas IGF-IR inhibitors more selectively inhibited growth in colon cancer lines. Finally, specific phenotypes play an important role in cellular response profiles. For example, luminal breast cancer cells (nine of nine; 100%) segregated from basal cells (six of seven; 86%). The convergence of a common cellular response profile for different molecules targeting the same oncogenic pathway substantiates a rational clinical path for patient populations most likely to benefit from treatment. Cancer Res; 70(9); 3677-86. (c)2010 AACR.
Similar articles
-
Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.Clin Cancer Res. 2006 Aug 1;12(15):4755-65. doi: 10.1158/1078-0432.CCR-05-2691. Clin Cancer Res. 2006. PMID: 16899627
-
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.Clin Cancer Res. 2009 Jul 15;15(14):4649-64. doi: 10.1158/1078-0432.CCR-09-0317. Epub 2009 Jun 30. Clin Cancer Res. 2009. PMID: 19567590
-
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.Clin Cancer Res. 2008 May 1;14(9):2673-80. doi: 10.1158/1078-0432.CCR-07-1046. Clin Cancer Res. 2008. PMID: 18451231 Clinical Trial.
-
The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S45-56. doi: 10.1007/s00280-003-0593-0. Epub 2003 Jun 18. Cancer Chemother Pharmacol. 2003. PMID: 12819933 Review.
-
Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.Semin Oncol. 2009 Dec;36 Suppl 3:S3-S17. doi: 10.1053/j.seminoncol.2009.10.011. Semin Oncol. 2009. PMID: 19963098 Review.
Cited by
-
A single-sample microarray normalization method to facilitate personalized-medicine workflows.Genomics. 2012 Dec;100(6):337-44. doi: 10.1016/j.ygeno.2012.08.003. Epub 2012 Aug 19. Genomics. 2012. PMID: 22959562 Free PMC article.
-
Predict drug sensitivity of cancer cells with pathway activity inference.BMC Med Genomics. 2019 Jan 31;12(Suppl 1):15. doi: 10.1186/s12920-018-0449-4. BMC Med Genomics. 2019. PMID: 30704449 Free PMC article.
-
Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.Mol Oncol. 2017 Sep;11(9):1156-1171. doi: 10.1002/1878-0261.12086. Epub 2017 Jul 5. Mol Oncol. 2017. PMID: 28556483 Free PMC article.
-
New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels.Sci Rep. 2017 Nov 9;7(1):15126. doi: 10.1038/s41598-017-14770-6. Sci Rep. 2017. PMID: 29123141 Free PMC article.
-
Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours.PeerJ. 2015 Feb 26;3:e788. doi: 10.7717/peerj.788. eCollection 2015. PeerJ. 2015. PMID: 25755924 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous